Key Insights

Highlights

Success Rate

93% trial completion (above average)

Published Results

316 trials with published results (28%)

Research Maturity

784 completed trials (69% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

5.2%

59 terminated out of 1130 trials

Success Rate

93.0%

+6.5% vs benchmark

Late-Stage Pipeline

28%

311 trials in Phase 3/4

Results Transparency

40%

316 of 784 completed with results

Key Signals

316 with results93% success59 terminated

Data Visualizations

Phase Distribution

854Total
Not Applicable (173)
Early P 1 (14)
P 1 (162)
P 2 (194)
P 3 (169)
P 4 (142)

Trial Status

Completed784
Unknown108
Recruiting76
Terminated59
Not Yet Recruiting34
Active Not Recruiting33

Trial Success Rate

93.0%

Benchmark: 86.5%

Based on 784 completed trials

Clinical Trials (1130)

Showing 20 of 20 trials
NCT06599411Recruiting

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

NCT07582783RecruitingPrimary

A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania

NCT07642544Not Yet RecruitingPrimary

Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis

NCT03816345Phase 1Recruiting

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT06999941Enrolling By InvitationPrimary

A Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous Features

NCT06357221Phase 4Completed

A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients

NCT07487831Phase 4Not Yet Recruiting

The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease

NCT07623486Phase 1Active Not RecruitingPrimary

Trial of HSK44459 Cream for the Management Plaque Psoriasis

NCT03451851Phase 3Active Not RecruitingPrimary

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

NCT01778569Completed

The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI)

NCT00508547Active Not RecruitingPrimary

Psoriasis Longitudinal Assessment and Registry

NCT07626788Not ApplicableNot Yet RecruitingPrimary

Pentoxifylline Add-On Therapy for Mild-to-Moderate Plaque Psoriasis

NCT03218488Active Not RecruitingPrimary

A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis

NCT06857942Phase 4RecruitingPrimary

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

NCT06399432Not ApplicableRecruitingPrimary

Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors

NCT07352566Phase 4Not Yet RecruitingPrimary

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT05701995Phase 4CompletedPrimary

A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

NCT05621369Active Not Recruiting

Psorcast Mobile Study

NCT05908240Not ApplicableActive Not RecruitingPrimary

Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis

NCT04864886Recruiting

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

Scroll to load more

Research Network

Activity Timeline